Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moDACTINOMYCIN (dactinomycin) by Recordati is synthesis. Approved for part of a multi-phase, combination chemotherapy regimen, nonseminomatous testicular cancer and 6 more indications. First approved in 2013.
Drug data last refreshed 20h ago
synthesis. The cytotoxic activity of dactinomycin has been demonstrated in animal models of different human cancers.
Worked on DACTINOMYCIN at Recordati? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo